Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › Macupatide

Macupatide

GIP · s.c. · Eli Lilly

Data cut 12 November 2026 · page built 16 November 2026 · 0 trial arms · 0 trials with results · 0 registered trials · see on the pipeline board

Summary

Also known as
LY3532226, Eli Lilly
Mechanism
GIP
Route
s.c.
Company
Eli Lilly
Highest development stage
phase 2
Status (as of data cut)
Phase 2 (alone and with eloralintide) verify
Next milestone
Phase 2 results

Sources for the status

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity1 phase 2 / signalPhase 2, alone and with eloralintideMacupatide ± eloralintide phase 2
T2D0 no data
CV outcomes0 no data
CKD0 no data
HFpEF0 no data
MASH0 no data
Sleep apnoea0 no data
Knee OA0 no data
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

No trial arms with extracted efficacy or tolerability data yet.

Primary sources

No source recorded.

How to cite this page

Medical Adviser's Group. Incretin Atlas: Macupatide. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/macupatide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.